| Returns | 1W : 10% , 1M : 17.5%,1Y : 154.3% |
| Peers & Returns | 1W | 1M | 1Y |
| NEULAND LABORATORIES LTD | 10% | 17.5% | 154.3% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | -2.7% | 4.8% | 35.3% |
| DR REDDYS LABORATORIES LTD | -3.9% | 3.4% | 81.9% |
| DIVIS LABORATORIES LTD | -4.7% | -2.1% | 99.6% |
| CIPLA LTD | -3.9% | 4.7% | 73.8% |
| BIOCON LTD | -3% | -0.7% | 65.8% |
| AUROBINDO PHARMA LTD | -3% | 6.9% | 97.4% |
| LUPIN LTD | 1.6% | 13.8% | 47.2% |
| TORRENT PHARMACEUTICALS LTD | -4.9% | -2.7% | 46.9% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
111.03
P/E Calculated based on EPS of 12.38
[ Mar2020 - Standalone Results ] 2.5
P/B Calculated based on Book Value of 549.21
[ Mar2020 - Standalone Results ] 2.24
P/S Calculated based on Revenues of 787.128 Cr
[ TTM - Standalone Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
120% 73% 88% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.37 0.33 1.31 0.67 |
0.37 0.33 1.3 0.67 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
4.3 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Standalone | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
17.51% 20.13% 41.49% 41.74% |
29.63% 62.83% 131.65% 148.86% |
| QtrlyTrend |
8
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
